The FDA is hosting a workshop to communicate regulatory concerns and considerations with using non-clinical assays for comparative immunogenicity risk assessment. In addition, this workshop seeks to generate discussions on the following four sessions/topics: In silico methods to assess binding affinity to MHC.
